Literature DB >> 1739911

Lymphoma in inflammatory bowel disease.

A J Greenstein1, G E Mullin, J A Strauchen, T Heimann, H D Janowitz, A H Aufses, D B Sachar.   

Abstract

Nine patients with lymphoma occurring in association with inflammatory bowel disease were admitted to The Mount Sinai Hospital between 1960 and 1983. Five (two men and three women) occurred among 1156 patients (0.43%) with ulcerative colitis (UC) and four (men), among 1480 patients (0.27%) with Crohn's disease (CD), a strong male preponderance in the latter group. In all four of the patients with CD and in four of the five patients with UC, the lymphomas were extraintestinal. The mean age of onset of UC in these patients was late (46 years, 19 years older than in our overall series), with lymphomas occurring a mean of only 12 years later. By contrast, patients with CD had bowel disease much younger (mean age, 26 years), and their lymphomas appeared after a longer disease duration (mean, 24 years). The risk factors for the one patient with colonic lymphoma were similar to those with colitis-associated colorectal carcinoma: extensive and long-standing colitis and relatively young age when malignant disease developed. Four of the patients with lymphoma had associated colonic carcinoma; in three of them, the carcinoma appeared within the first decade of colitis, an unusual occurrence. A second malignant lesion also occurred in three patients with UC.

Entities:  

Mesh:

Year:  1992        PMID: 1739911     DOI: 10.1002/cncr.2820690510

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.

Authors:  R J Farrell; Y Ang; P Kileen; D S O'Briain; D Kelleher; P W Keeling; D G Weir
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

2.  A steroid-refractory ulcerative colitis revealing Epstein-Barr virus/cytomegalovirus-positive colonic lymphoma.

Authors:  Fady Daniel; Diane Damotte; Henri Moindrot; Thierry Molina; Anne Berger; Christophe Cellier
Journal:  Int J Colorectal Dis       Date:  2005-03-04       Impact factor: 2.571

Review 3.  Is there truly a risk of lymphoma from biologic therapies?

Authors:  Erica Dommasch; Joel M Gelfand
Journal:  Dermatol Ther       Date:  2009 Sep-Oct       Impact factor: 2.851

Review 4.  Lower gastrointestinal malignancy in Crohn's disease.

Authors:  W R Connell; J P Sheffield; M A Kamm; J K Ritchie; P R Hawley; J E Lennard-Jones
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

5.  Renal lymphoma: an unusual cause of extrahepatic biliary obstruction.

Authors:  Z Abbas; D A Johnston; F E Murray
Journal:  Postgrad Med J       Date:  1996-10       Impact factor: 2.401

6.  The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease.

Authors:  Anthony O'Connor; Asghar Qasim; Colm A O'Moráin
Journal:  Ther Adv Chronic Dis       Date:  2010-01       Impact factor: 5.091

Review 7.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary.

Authors:  Lindsay A Schmidt; Megan S Lim
Journal:  J Hematop       Date:  2009-03-18       Impact factor: 0.196

9.  Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.

Authors:  T Ljung; P Karlén; D Schmidt; P M Hellström; A Lapidus; I Janczewska; U Sjöqvist; R Löfberg
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

Review 10.  Thiopurines in inflammatory bowel disease revisited.

Authors:  Florian Bär; Christian Sina; Klaus Fellermann
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.